Introductory Chapter: Insights into Urinary Disorders
Reference29 articles.
1. Apodaca G. The uroepithelium: Not just a passive barrier. Traffic. 2004;5(3):117-128
2. Go AS, Tan TC, Chertow GM, Ordonez JD, Fan D, Law D, et al. Primary nephrotic syndrome and risks of ESKD, cardiovascular events, and death: The kaiser permanente nephrotic syndrome study. J Am Soc Nephrol. 2021;32(9):2303-2314
3. Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. The New England Journal of Medicine. 2009;361(1):11-21
4. Tomas NM, Beck LH Jr, Meyer-Schwesinger C, Seitz-Polski B, Ma H, Zahner G, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. The New England Journal of Medicine. 2014;371(24):2277-2287
5. Bomback AS. Management of membranous nephropathy in the PLA2R era. Clinical Journal of the American Society of Nephrology. 2018;13(5):784-786